Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Room 1001, Toronto M5S3M2, Ontario, Canada.
Trends Pharmacol Sci. 2010 Jan;31(1):22-35. doi: 10.1016/j.tips.2009.10.001. Epub 2009 Dec 11.
Treatment of human immunodeficiency virus (HIV) infection involves a combination of several antiviral agents belonging to different pharmacological classes. This combination is referred to as highly active antiretroviral therapy (HAART). This treatment has proved to be very effective in suppressing HIV replication, but antiretroviral drugs have complex pharmacokinetic properties involving extensive drug metabolism and transport by membrane-associated drug carriers. Combination drug therapy often introduces complex drug-drug interactions that can result in toxic or sub-therapeutic drug concentrations, compromising treatment. This review focuses on the role of ATP-binding cassette (ABC) membrane-associated efflux transporters and solute carrier (SLC) uptake transporters in antiretroviral drug disposition, and identifies clinically important antiretroviral drug-drug interactions associated with changes in drug transport.
治疗人类免疫缺陷病毒（HIV）感染需要联合使用几种属于不同药理学类别的抗病毒药物。这种联合治疗被称为高效抗逆转录病毒治疗（HAART）。这种治疗方法已被证明在抑制 HIV 复制方面非常有效，但抗逆转录病毒药物具有复杂的药代动力学特性，涉及膜相关药物载体的广泛药物代谢和转运。联合药物治疗常常会引入复杂的药物相互作用，导致毒性或治疗效果不佳的药物浓度，从而影响治疗效果。这篇综述重点介绍了 ATP 结合盒（ABC）膜相关外排转运体和溶质载体（SLC）摄取转运体在抗逆转录病毒药物处置中的作用，并确定了与药物转运变化相关的临床上重要的抗逆转录病毒药物-药物相互作用。
